Anti-IL4 Monoclonal antibody, clone 9E5-9 [PE/Cy7®]

Self-healing ionogel is a promising smart material because of its high conductivity and reliable stimuli responsiveness upon mechanical damage. However, self-healing ionogels possessing rapid, complete recovery properties and multifunctionality are still limited. Herein, we designed a new D-gluconic acetal-based gelator (PB8) bearing a urea group in the alkyl side chain. Interestingly, the balance between hydrophilicity and hydrophobicity of the molecule is achieved. Thus, PB8 could form transparent ionogels because of its excellent affinity to ionic liquids (ILs), which exhibited appropriate mechanical strength, high viscoelasticity, and efficient self-healing properties. The presence of synergistic effects from hydrogen bonding, pi-pi stacking, and interactions between the urea-containing side chains was responsible for the self-assembly of gelators in ILs and the self-healing property mainly related to the side chains of PB8. Interestingly, the transparent PB8-IL4 ionogel possessed high conductivity and mechanical strength, moldable and injectable properties, and rapid and complete self-healing characteristics (complete recovery within 14 min), which showed excellent performance as a smart ionic conductor. Furthermore, the self-healing PB8-based ionogels with anticorrosion properties are a remarkable lubricating material in the steel-steel contact and exhibited excellent lubricating performances. Overall, an efficient PB8-based ionogel with self-healing properties has been developed for potential use both as a smart electrical conductor and as a high-performance lubricating material. The unique structure of PB8 bearing a urea group in the side chain is found to be responsible for the multifunctional ionogel formation.

Neurodegenerative disorders present a broad group of neurological diseases and remain one of the greatest challenges and burdens to mankind. Maladies like amyotrophic lateral sclerosis, Alzheimer's disease, stroke or spinal cord injury commonly features astroglia involvement (astrogliosis) with signs of inflammation. Regenerative, paracrine and immunomodulatory properties of human mesenchymal stromal cells (hMSCs) could target the above components, thus opening new therapeutic possibilities for regenerative medicine. A special interest should be given to hMSCs derived from the umbilical cord (UC) tissue, due to their origin, properties and lack of ethical paradigms. The aim of this study was to establish standard operating and scale-up good manufacturing practice (GMP) protocols of UC-hMSCs isolation, characterization, expansion and comparison of cells' properties when harvested on T-flasks versus using a large-scale bioreactor system. Human UC-hMSCs, isolated by tissue explant culture technique from Wharton's jelly, were harvested after reaching 75% confluence and cultured using tissue culture flasks. Obtained UC-hMSCs prior/after the cryopreservation and after harvesting in a bioreactor, were fully characterized for "mesenchymness" immunomodulatory, tumorigenicity and genetic stability, senescence and cell-doubling properties, as well as gene expression features. Our study demonstrates an efficient and simple technique for large scale UC-hMSCs expansion. Harvesting of UC-hMSCs' using classic and large scale methods did not alter UC-hMSCs' senescence, genetic stability or in vitro tumorigenicity features. We observed comparable growth and immunomodulatory capacities of fresh, frozen and expanded UC-hMSCs. We found no difference in the ability to differentiate toward adipogenic, osteogenic and chondrogenic lineages between classic and large scale UC-hMSCs expansion methods. Both, methods enabled derivation of genetically stabile cells with typical mesenchymal features. Interestingly, we found significantly increased mRNA expression levels of neural growth factor (NGF) and downregulated insulin growth factor (IGF) in UC-hMSCs cultured in bioreactor, while IL4, IL6, IL8, TGFb and VEGF expression levels remained at the similar levels. A culturing of UC-hMSCs using a large-scale automated closed bioreactor expansion system under the GMP conditions does not alter basic "mesenchymal" features and quality of the cells. Our study has been designed to pave a road toward translation of basic research data known about human UC-MSCs for the future clinical testing in patients with neurological and immunocompromised disorders. An industrial manufacturing of UC-hMSCs next will undergo regulatory approval following advanced therapy medicinal products (ATMP) criteria prior to clinical application and approval to be used in patients.